Optimizing Care for Patients With Lupus Nephritis

This activity was originally presented live at Asembia's AXS26 Summit in Las Vegas, Nevada

Program Description

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneous presentation. Lupus nephritis (LN) is a severe manifestation of SLE that presents with proteinuria, hematuria, and impaired kidney function. LN is a primary driver of morbidity and mortality, and guidelines support early reduction in proteinuria to improve long-term outcomes and reduce risk of disease flares. This program dives into the intricate landscape of SLE and LN, beginning with the clinical manifestations and the burden of organ damage caused by chronic inflammation and discussing limitations associated with standard-of-care corticosteroids and immunosuppressants. Expert faculty will discuss the evolving management paradigm for SLE and LN, with updated recommendations for reducing corticosteroid exposure, as recommendations transition to include recently approved and investigational biologics with novel mechanisms of action. By aligning with recent guidelines, this session equips pharmacists to address the significant economic impact of SLE and LN driven by frequent hospitalizations and high health care resource utilization while defining their critical role within the multidisciplinary team. The discussion will encompass best practices to optimize patient pathways through monitoring, medication therapy management, and the application of evidence-based strategies to reduce flares and improve long-term quality of life for patients with SLE and LN.

Target audience: Specialty pharmacists
Type of Activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Foundational
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the epidemiology and pathophysiology of systemic lupus erythematosus (SLE) and lupus nephritis (LN) and the impact of disease progression on patient outcomes 
• Apply updated clinical guidelines and new pharmacotherapy for the treatment of SLE and LN
• Employ new and emerging therapies into patient care in coordination with the multidisciplinary care team using an evidence-based approach that will optimize outcomes and rationally allocate health care resources for the treatment of SLE and LN

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.14 CEU) under the ACPE universal activity number 0290-0000-26-123-H01-P. The activity is available for CE credit through May 12, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

The following contributors have no relevant financial relationships with ineligible companies to disclose: 

Shivani Garg, MD, PhD

Yuqian Liu, PharmD

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Liza Patel, PharmD, RPh; Kylie Ferentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms